Cell 2025 is Oxford Global’s flagship event, bringing together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell & gene therapy value chain. Covering everything from discovery and development to manufacturing and commercialization, this event explores cutting-edge innovations in automation, AI-driven bioprocessing, and emerging cell-based therapies. With dedicated programs on Cell Culture & Bioprocessing, Advanced Therapy Development, and Cell & Gene Therapy Manufacturing, attendees will gain critical insights into the future of advanced therapies.
We’re excited to attend this premier gathering and connect with industry pioneers shaping the next generation of cell and gene therapies. With 1,000+ attendees, 230 hours of pre-arranged meetings, and 13+ hours of networking, this event offers unparalleled opportunities to collaborate and stay ahead of breakthrough advancements. Register today!
SPEAKER PRESENTATION
Our CTO, Richard Hammond, will share his thoughts in the panel session: “Innovations & Challenges In Upstream Bioprocessing: Navigating The Future Of Cell Culture & Bioprocessing.”
SPEAKER PRESENTATION
Title: Enabling ultra-high throughput screening for therapeutic cell engineering and selection with Cyto-Mine® Chroma
Summary: Development of CAR-T therapies relies on two core processes: high-efficiency gene editing and selection of edited cells with the required functional capabilities from a population. In this talk we will introduce Cyto-Mine® Chroma, a novel platform for assessing cell function and selecting high-performing cells quickly and easily. We will also introduce a new Cyto-Mine upgrade module in development to allow high-throughput gene editing workflows and cell-cell functional interaction studies.
Richard Hammond
Chief Technical Officer
Sphere Bio
